Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer

This study has been completed.
National Cancer Institute (NCI)
Southwest Oncology Group
Cancer and Leukemia Group B
Information provided by:
Eastern Cooperative Oncology Group Identifier:
First received: December 7, 2001
Last updated: January 26, 2010
Last verified: January 2010

RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as ketoconazole may stop the production of androgens. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether hormone therapy is more effective than combination chemotherapy in treating prostate cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of hormone therapy with that of combination chemotherapy in treating patients who have prostate cancer that has been previously treated with androgen suppression.

Condition Intervention Phase
Prostate Cancer
Drug: docetaxel
Drug: estramustine phosphate sodium
Drug: ketoconazole
Drug: therapeutic hydrocortisone
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment
Official Title: A Phase III Randomized Trial for Evaluating Second Line Hormonal Therapy (Ketoconazole/Hydrocortisone) Versus Paclitaxel/Estramustine Combination Chemotherapy on Progression Free Survival in Asymptomatic Patients With a Rising PSA After Hormonal Therapy for Prostate Cancer

Resource links provided by NLM:

Further study details as provided by Eastern Cooperative Oncology Group:

Study Start Date: May 2003
Primary Completion Date: December 2004 (Final data collection date for primary outcome measure)
Detailed Description:


  • Compare time to objective progression in patients with prostate cancer and a rising prostate-specific antigen (PSA) after androgen suppression when treated with second-line hormonal therapy (ketoconazole and hydrocortisone) vs combination chemotherapy (docetaxel and estramustine).
  • Compare time to PSA progression and correlate this with time to objective progression in patients treated with these regimens.
  • Compare the quality of life in patients treated with these regimens.
  • Compare overall survival of patients treated with these regimens.
  • Compare the natural history of progression in patients treated with these regimens.
  • Identify prognostic indicators of clinical outcome by immunohistochemical evaluation of apoptopic biomarkers in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to prior treatment with bisphosphonates (yes vs no). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive oral ketoconazole three times daily and oral hydrocortisone twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive oral estramustine three times daily on days 1-5 and docetaxel IV over 1 hour on day 2. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, on day 1 of week 9, at 6 months and 1 year, and then annually for up to 10 years or until beginning of first non-protocol therapy.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually for 5 years.

PROJECTED ACCRUAL: A total of 590 patients (295 per treatment arm) will be accrued for this study within 4 years.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No


  • Histologically confirmed adenocarcinoma of the prostate that was continuously treated with androgen suppression
  • Rising prostate-specific antigen (PSA), defined as PSA > 5 ng/mL, rising on 2 consecutive measurements at least 4 weeks apart
  • Gleason score 7 or higher and/or seminal vesicle involvement at diagnosis
  • Patients previously treated with antiandrogen or glucocorticoid therapy must meet the following criteria:

    • Must show a continued rise in PSA after stopping antiandrogen (flutamide, bicalutamide, or nilutamide) or glucocorticoid (dexamethasone or prednisone)

      • At least 4 weeks continued rise in PSA after flutamide or nilutamide (6 weeks for bicalutamide)
  • Testosterone less than 50 ng/dL

    • Patients who have not undergone surgical castration must continue primary androgen suppression to maintain castrate levels of testosterone
  • No progressive or measurable local or metastatic disease (including bone metastases)



  • 18 and over

Performance status:

  • ECOG 0-1

Life expectancy:

  • Not specified


  • Granulocyte count at least 2,000/mm^3
  • Platelet count at least 100,000/mm^3


  • SGOT no greater than 2 times upper limit of normal
  • Bilirubin no greater than 1.5 mg/dL


  • Creatinine no greater than 1.7 mg/dL


  • No American Heart Association class III or IV heart disease
  • No uncontrolled congestive heart failure
  • No life-threatening cardiac arrhythmias


  • Fertile patients must use effective contraception
  • No other prior malignancy unless curatively treated and disease-free for appropriate time period for specific cancer
  • No preexisting peripheral neuropathy greater than grade 1
  • No known hypersensitivity to polysorbate 80


Biologic therapy:

  • Not specified


  • At least 5 years since prior systemic chemotherapy

Endocrine therapy:

  • See Disease Characteristics
  • At least 4 weeks since prior hydrocortisone
  • No prior ketoconazole


  • At least 28 days since prior radiotherapy to primary site
  • No prior palliative radiotherapy
  • No concurrent radiotherapy


  • See Disease Characteristics


  • Recovered form prior therapy
  • At least 7 days since prior parenteral antibiotics for active infection
  • No concurrent digitalis
  • No concurrent H_2 blockers or proton pump inhibitors (arm I only)
  • Concurrent bisphosphonates allowed provided they were initiated prior to study therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00027859

  Show 98 Study Locations
Sponsors and Collaborators
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Southwest Oncology Group
Cancer and Leukemia Group B
Study Chair: Michael A. Carducci, MD Sidney Kimmel Comprehensive Cancer Center
Study Chair: Nirmala Bhoopalam, MD Veterans Affairs Medical Center - Hines
Study Chair: Gregory P. Swanson, MD Deaconess Medical Center, Spokane, Washington
Study Chair: William Dahut, MD National Cancer Institute (NCI)
  More Information

Responsible Party: Group Chair, Eastern Cooperative Oncology Group Identifier: NCT00027859     History of Changes
Other Study ID Numbers: CDR0000069088
Study First Received: December 7, 2001
Last Updated: January 26, 2010

Keywords provided by Eastern Cooperative Oncology Group:
adenocarcinoma of the prostate
stage III prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Hydrocortisone 17-butyrate 21-propionate
Cortisol succinate
Hydrocortisone acetate
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inhibitors
Antineoplastic Agents, Alkylating
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Anti-Inflammatory Agents processed this record on April 24, 2017